GO:0032243 negative regulation of nucleoside transport: Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032243 describes any process that stops, prevents, or reduces the directed movement of a nucleoside into, out of, or within a cell.
• Nucleoside transport is primarily mediated by SLC28 (concentrative) and SLC29 (equilibrative) transporter families, and their negative regulation controls intracellular nucleoside pools.
• The c-Jun N-terminal kinase (JNK) pathway directly regulates ENT1 (SLC29A1) expression and ENT1-dependent nucleoside transport, providing a mechanistic example of negative regulation.
• Adenosine signaling, a key nucleoside pathway, is modulated by ATP-sensitive K+ channels in CNS capillaries, linking nucleoside transport regulation to vascular and neurological function.
• Dysregulated nucleoside transport contributes to gemcitabine resistance in pancreatic cancer and non-small cell lung cancer, where SLC38A5 and SLC7A11 modulate ferroptosis and drug response.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect causal roles of transport regulators in disease and drug resistance.
Description
Nucleosides are fundamental building blocks of nucleic acids and key signaling molecules, and their movement across cellular membranes is tightly controlled by dedicated transport proteins. The Gene Ontology term GO:0032243, negative regulation of nucleoside transport, captures any process that stops, prevents, or reduces the frequency, rate, or extent of the directed movement of a nucleoside into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore. This regulatory process is critical because nucleoside availability influences DNA synthesis, RNA metabolism, and extracellular signaling, and its dysregulation is implicated in cancer chemoresistance and immune escape. Mechanistically, negative regulation of nucleoside transport can occur through transcriptional repression of transporter genes, post-translational modification of transporter proteins, or indirect modulation of transport activity by signaling kinases. For example, the c-Jun N-terminal kinase (JNK) pathway regulates ENT1 (SLC29A1) expression and ENT1-dependent nucleoside transport, demonstrating a direct link between stress signaling and nucleoside flux. In the CNS, adenosine signaling activates ATP-sensitive K+ channels in endothelial cells and pericytes, illustrating how nucleoside-mediated signaling intersects with vascular tone and neurovascular coupling. For researchers, GO:0032243 provides a framework to study how cells adapt nucleoside uptake and efflux under stress, during immune responses, and in drug-treated tumors. Understanding this regulation is essential for developing strategies to overcome chemoresistance, modulate immune responses, and target metabolic vulnerabilities in cancer and other diseases.
negative regulation of nucleoside transport At A Glance
| GO ID | GO:0032243 |
|---|---|
| GO term | negative regulation of nucleoside transport |
| Ontology | biological_process |
| Synonym | down regulation of nucleoside transport, down-regulation of nucleoside transport, downregulation of nucleoside transport, inhibition of nucleoside transport |
| Major function | Reduces the directed movement of nucleosides into, out of, or within a cell, or between cells, via transporters or pores |
| Related transporters | SLC28 (concentrative nucleoside transporters) and SLC29 (equilibrative nucleoside transporters) families |
| Key signaling regulator | c-Jun N-terminal kinase (JNK) regulates ENT1 (SLC29A1) expression and ENT1-dependent nucleoside transport |
| Disease relevance | Chemoresistance in pancreatic cancer and non-small cell lung cancer; immune escape in cervical cancer |
What Is GO:0032243?
GO:0032243, negative regulation of nucleoside transport, is a biological process that encompasses any mechanism which stops, prevents, or reduces the frequency, rate, or extent of the directed movement of a nucleoside into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore. This includes downregulation of transporter gene expression, inhibition of transporter activity, and indirect signaling events that suppress nucleoside flux.
Why Is negative regulation of nucleoside transport Important in Cell Biology?
Negative regulation of nucleoside transport is important because nucleosides are central to nucleic acid synthesis, energy metabolism, and extracellular signaling, and their transport must be precisely controlled to maintain cellular homeostasis. Dysregulation of this process can alter drug sensitivity, as seen in gemcitabine-resistant cancers where transporters and ferroptosis regulators are modulated. Moreover, adenosine signaling, which depends on nucleoside transport, influences vascular function and immune responses, making this GO term relevant to cancer, immunology, and neuroscience.
• Controls intracellular nucleoside pools required for DNA and RNA synthesis.
• Regulates extracellular adenosine levels, impacting signaling in the CNS and immune system.
• Modulates sensitivity to nucleoside analog drugs such as gemcitabine.
• Influences ferroptosis, a form of cell death, through metabolic and transport pathways.
• Plays a role in immune escape of cancer cells via lactate and nucleoside metabolism.
• Is linked to chemoresistance in pancreatic cancer and non-small cell lung cancer.
• Provides targets for therapeutic intervention in cancer and inflammatory diseases.
• Helps explain inter-individual differences in drug response and toxicity.
• Connects stress kinase signaling (JNK) to metabolic transport regulation.
• Offers a framework for studying transporter regulation in diverse cell types.
What Happens During negative regulation of nucleoside transport?
Initiation by stress or signaling cues
In simple terms: A cell receives a signal that tells it to take up fewer nucleosides.
Negative regulation of nucleoside transport can be initiated by stress-activated signaling pathways. For instance, the c-Jun N-terminal kinase (JNK) pathway regulates ENT1 expression and ENT1-dependent nucleoside transport, leading to reduced transport activity. This initiation step often involves kinase cascades that respond to environmental stress, cytokines, or metabolic changes.
Transcriptional repression of transporter genes
In simple terms: The cell makes fewer transporter proteins by turning down the genes that encode them.
One major mechanism is reduced transcription of nucleoside transporter genes such as SLC29A1 (ENT1). JNK signaling has been shown to regulate ENT1 expression, providing a direct example of transcriptional control in negative regulation of nucleoside transport. Other transcription factors and epigenetic modifiers may also contribute, though specific factors vary by cell type.
Post-translational modification and trafficking
In simple terms: Existing transporter proteins can be modified or moved away from the cell surface to reduce transport.
Beyond transcription, transporters can be regulated post-translationally. Phosphorylation, ubiquitination, or altered trafficking can reduce the number of functional transporters at the plasma membrane. While specific ubiquitin ligases for nucleoside transporters are not fully defined in the provided literature, the principle of post-translational control is well established for membrane transporters.
Indirect modulation via metabolic and signaling networks
In simple terms: Other cellular pathways can indirectly shut down nucleoside transport.
Negative regulation can also occur indirectly through changes in ATP-sensitive K+ channels and adenosine signaling, as seen in CNS capillaries where adenosine signaling activates these channels. Additionally, metabolic regulators such as SLC38A5 and SLC7A11 influence ferroptosis and drug resistance, which may intersect with nucleoside transport regulation. These indirect mechanisms highlight the integration of nucleoside transport with broader metabolic and signaling networks.
Key Genes Involved in GO:0032243 negative regulation of nucleoside transport
The following genes and proteins are experimentally linked to nucleoside transport regulation, signaling, or related disease processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC29A1 (ENT1) | Equilibrative nucleoside transporter; regulated by JNK | Direct target for studying negative regulation of nucleoside transport |
| SLC28A1 (CNT1) | Concentrative nucleoside transporter | Potential mediator of nucleoside uptake regulation |
| SLC28A2 (CNT2) | Concentrative nucleoside transporter | May contribute to tissue-specific nucleoside transport |
| SLC28A3 (CNT3) | Concentrative nucleoside transporter | Broad selectivity transporter; relevant to drug transport |
| SLC29A2 (ENT2) | Equilibrative nucleoside transporter | Facilitates nucleoside and nucleobase transport |
| SLC29A3 (ENT3) | Equilibrative nucleoside transporter | Intracellular transporter; linked to lysosomal nucleoside transport |
| SLC29A4 (ENT4) | Equilibrative nucleoside transporter | pH-dependent transporter; may affect adenosine signaling |
| JNK (MAPK8/9/10) | Stress-activated kinase regulating ENT1 expression | Key upstream regulator of negative regulation |
| SLC38A5 | Amino acid transporter modulating ferroptosis and gemcitabine resistance | Links transport regulation to chemoresistance |
| SLC7A11 | Cystine/glutamate transporter; regulates ferroptosis | Modulates drug resistance and redox balance |
| PARP7 (TiPARP) | Negatively regulates type I interferon response | Connects nucleoside metabolism to immune signaling |
| YTHDF1 | m6A reader boosting lactate accumulation and immune escape | Links RNA modification to metabolic transport |
| KDM6B | Histone demethylase regulating SLC7A11 transcription | Epigenetic regulator of transport-related genes |
| GATA3 | Transcription factor regulating SLC7A11 | Transcription factor in ferroptosis and transport |
| WWP1 | E3 ubiquitin ligase targeting SLC7A11 | Post-translational regulator of transport proteins |
| Linc01833 | Long non-coding RNA shielding SLC7A11 from ubiquitination | RNA-based regulator of transport and drug resistance |
| Adenosine receptors (ADORA1/2A/2B/3) | Mediate adenosine signaling activating K+ channels | Link nucleoside signaling to vascular function |
How Is negative regulation of nucleoside transport Regulated?
Negative regulation of nucleoside transport is controlled at multiple levels. The JNK signaling pathway directly regulates ENT1 expression and ENT1-dependent nucleoside transport, providing a kinase-driven mechanism. Adenosine signaling activates ATP-sensitive K+ channels in CNS capillaries, indirectly influencing nucleoside-mediated vascular responses. Additionally, metabolic and epigenetic regulators such as SLC38A5, SLC7A11, KDM6B, GATA3, and YTHDF1 modulate ferroptosis and immune escape, which can intersect with nucleoside transport pathways. PARP7 also negatively regulates type I interferon responses, linking nucleoside metabolism to innate immunity.
negative regulation of nucleoside transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC38A5 | Pancreatic cancer gemcitabine resistance | Knockout and overexpression in pancreatic cancer cell lines |
| SLC7A11 | Non-small cell lung cancer gemcitabine resistance | Knock-in of ubiquitination-resistant mutant |
| YTHDF1 | Cervical cancer immune escape | Knockout in cervical cancer cells |
| PARP7 | Antitumor immunity and interferon response | Knockout and point mutation in cancer cells |
| ENT1 (SLC29A1) | Nucleoside transport regulation | Knockout and JNK-pathway perturbation |
Cancer chemoresistance
Negative regulation of nucleoside transport contributes to chemoresistance in pancreatic cancer and non-small cell lung cancer. SLC38A5 modulates ferroptosis to overcome gemcitabine resistance in pancreatic cancer, while Linc01833 drives gemcitabine resistance in NSCLC by shielding SLC7A11 from WWP1-mediated ubiquitination and inhibiting ferroptosis. These findings highlight how transport regulation and ferroptosis intersect to determine drug response.
Immune escape and tumor microenvironment
Nucleoside transport and metabolism influence immune escape. YTHDF1 boosts lactate accumulation to potentiate cervical cancer cell immune escape, and PARP7 negatively regulates the type I interferon response, with its inhibition triggering antitumor immunity. These mechanisms link nucleoside-related metabolic pathways to immune evasion.
Neurological and vascular function
Adenosine signaling activates ATP-sensitive K+ channels in endothelial cells and pericytes in CNS capillaries, demonstrating that nucleoside transport regulation is integral to neurovascular coupling and brain homeostasis. Dysregulation of adenosine transport may therefore impact neurological and vascular disorders.
From negative regulation of nucleoside transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a transporter regulator increase nucleoside transport? | CRISPR knockout of candidate gene in cell lines |
| Does a specific phosphorylation site control transporter activity? | Point mutation knock-in of phospho-deficient or phospho-mimetic residues |
| Does a disease-associated variant alter transport? | Knock-in of patient-derived mutations |
| Where is the transporter localized under regulation? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of a regulator reduce transport? | Overexpression cell models |
| Can library screening identify new regulators? | CRISPR library screening with transport readout |
How to Study the negative regulation of nucleoside transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Nucleoside uptake assay | Transport activity | Quantify negative regulation of nucleoside transport |
| RNA-seq | Transporter gene expression | Identify transcriptional repression |
| Ribo-seq | Translation efficiency | Assess translational control of transporters |
| Proteomics | Protein modifications and interactions | Map ubiquitination and phosphorylation |
| Fluorescence microscopy | Subcellular localization | Study transporter trafficking |
| CRISPR knockout | Gene function loss | Test causal role in transport regulation |
| CRISPR library screening | High-throughput gene function | Discover new regulators of nucleoside transport |
| Ferroptosis assays | Cell death and lipid peroxidation | Link transport regulation to ferroptosis |
Nucleoside transport assays
Radiolabeled or fluorescent nucleoside uptake assays measure transport activity directly. These assays can be used to quantify the effects of JNK pathway modulation on ENT1-dependent transport.
Transcriptional and post-transcriptional analysis
RNA-seq and qPCR measure transporter gene expression, while polysome profiling or Ribo-seq can assess translation efficiency. JNK regulation of ENT1 expression can be dissected using these methods.
Proteomics and post-translational modification mapping
Mass spectrometry-based proteomics can identify phosphorylation, ubiquitination, and other modifications on transporters. WWP1-mediated ubiquitination of SLC7A11 is an example of post-translational regulation that can be studied by proteomics.
Imaging and localization
Fluorescence microscopy with tagged transporters reveals subcellular localization and trafficking. Tagged knock-in models enable visualization of endogenous transporters under regulatory conditions.
How CRISPR Can Be Used to Study GO:0032243 negative regulation of nucleoside transport
Knockout
CRISPR knockout of candidate genes such as SLC29A1, SLC38A5, or SLC7A11 can determine whether they are required for negative regulation of nucleoside transport. For example, knockout of SLC38A5 modulates ferroptosis and gemcitabine sensitivity in pancreatic cancer cells.
Point Mutation
Point mutation knock-in can test the function of specific residues, such as phosphorylation sites in ENT1 or ubiquitination sites in SLC7A11. This approach helps dissect post-translational regulation of nucleoside transport.
Knock-in
Knock-in of tagged transporters or disease-associated variants allows tracking of endogenous proteins and assessment of variant effects on transport regulation. Tagged knock-in models are valuable for imaging and biochemical studies.
Overexpression
Overexpression of regulators such as YTHDF1 or Linc01833 can mimic disease states and test whether increased levels reduce nucleoside transport or alter drug resistance.
How EDITGENE Supports negative regulation of nucleoside transport Research
Researchers studying negative regulation of nucleoside transport-related genes often need to determine whether a candidate gene is causally involved in transport regulation, drug resistance, or immune escape. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes linked to GO:0032243.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of nucleoside transport research.
Frequently Asked Questions About negative regulation of nucleoside transport
What is GO:0032243?
GO:0032243 is the Gene Ontology term for negative regulation of nucleoside transport, describing any process that stops, prevents, or reduces the directed movement of a nucleoside into, out of, or within a cell, or between cells.
What genes are involved in negative regulation of nucleoside transport?
Key genes include SLC29A1 (ENT1), SLC28A1-3, SLC29A2-4, JNK, SLC38A5, SLC7A11, and regulators such as YTHDF1 and PARP7.
How is nucleoside transport negatively regulated?
It can be regulated by transcriptional repression, post-translational modification, and indirect signaling pathways such as JNK and adenosine signaling.
What diseases are linked to nucleoside transport regulation?
Cancer chemoresistance, immune escape, and neurological/vascular conditions are linked to dysregulated nucleoside transport.
Which transporters mediate nucleoside transport?
The SLC28 (concentrative) and SLC29 (equilibrative) families are the primary nucleoside transporters.
How does JNK regulate nucleoside transport?
JNK regulates ENT1 expression and ENT1-dependent nucleoside transport, providing a direct mechanism for negative regulation.
What is the role of SLC38A5 in gemcitabine resistance?
SLC38A5 modulates ferroptosis to overcome gemcitabine resistance in pancreatic cancer.
How does SLC7A11 affect drug resistance?
SLC7A11 is protected from WWP1-mediated ubiquitination by Linc01833, inhibiting ferroptosis and driving gemcitabine resistance in NSCLC.
Can CRISPR be used to study nucleoside transport regulation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect gene function in nucleoside transport.
What methods measure nucleoside transport activity?
Nucleoside uptake assays, RNA-seq, Ribo-seq, proteomics, and imaging are commonly used to measure transport and its regulation.
Conclusion
GO:0032243, negative regulation of nucleoside transport, is a critical biological process that controls nucleoside availability for nucleic acid synthesis, signaling, and drug response. Its dysregulation is implicated in cancer chemoresistance, immune escape, and neurovascular function, making it a compelling area for therapeutic targeting. By leveraging CRISPR-based models and multi-omics methods, researchers can uncover new regulators and translate these findings into clinical advances.
References
- 1. Kim MJ et al.. 2023. SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer.. Cells 12(20) PMID: 37887353
- 2. Gozgit JM et al.. 2021. PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity.. Cancer Cell 39(9):1214-1226.e10 PMID: 34375612
- 3. Leisewitz AV et al.. 2011. Regulation of ENT1 expression and ENT1-dependent nucleoside transport by c-Jun N-terminal kinase.. Biochem Biophys Res Commun 404(1):370-5 PMID: 21145879
- 4. Sancho M et al.. 2022. Adenosine signaling activates ATP-sensitive K(+) channels in endothelial cells and pericytes in CNS capillaries.. Sci Signal 15(727):eabl5405 PMID: 35349300
- 5. Xiong J et al.. 2024. YTHDF1 boosts the lactate accumulation to potentiate cervical cancer cells immune escape.. Cell Death Dis 15(11):843 PMID: 39557826
- 6. Zhang H et al.. 2025. N6-methyladenosine RNA modification regulates the transcription of SLC7A11 through KDM6B and GATA3 to modulate ferroptosis.. J Biomed Sci 32(1):8 PMID: 39800682
- 7. Wang CC et al.. 2026. Advances in TCDD-inducible poly(ADP-ribose) polymerase (TiPARP/PARP7) research: From molecular mechanisms to therapeutic applications.. Biochem Pharmacol 244:117618 PMID: 41365471
- 8. Ni L et al.. 2026. Linc01833 drives gemcitabine resistance in non-small cell lung cancer by shielding SLC7A11 from WWP1-mediated ubiquitination and inhibiting ferroptosis.. Drug Resist Updat 85:101351 PMID: 41494352
